Life Sciences in the Fight Against COVID-19

We are facing an unprecedented global health crisis - Life Sciences companies and the broader healthcare ecosystem, from those working in research and clinical development, to manufacturing and patient care are at the forefront of the race to contain and fight COVID-19.

• Research and Discovery: Faced with social distancing measures and workplace closures, biopharmaceutical companies, academic researchers and startups face a challenging environment where scientific collaboration and networking effectively with colleagues, partners and CROs has never been more important. Also important is the need for researchers to guide physical experimentation and accelerate the discovery and development of new therapeutics.

• Clinical Development: As COVID-19 has spread, it has had a global impact on clinical trials. There has been a profound impact on the industry both at a global level but also at the site level. Understanding what is happening on the ground is critical to define a path forward.

• Manufacturing: The COVID-19 pandemic has pushed Life Sciences manufacturers to rapidly shift gears, from addressing work-from-home policies to managing extreme swings in demand and uncertain supply chains. The use of platforms and marketplace catalyzes the development and manufacturing of vital medical equipment in the race to save the lives of those affected by the disease while keeping the frontline workers safe.

• Patient Care: The use of state‐of‐the‐art fluid simulation applications have been instrumental in keep patients and staff alike safe in Wuhan’s Leishenshan Hospital in China. Simulation technology like SIMULIA XFlow and the use of virtual worlds accelerates the building or extending of hospital facilities in a time of need for rapid deployment.